This article is more than 5 years old. Information may no longer be current.

Eyevance acquires Tobradex ST, Natacyn

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Eyevance Pharmaceuticals has acquired Tobradex ST and Natacyn from Novartis, according to a press release.

Tobradex ST (tobramycin 0.3%/dexamethasone 0.05% ophthalmic suspension), a fixed-dose topical antibiotic and corticosteroid combination for steroid-responsive inflammatory ocular conditions, and Natacyn (natamycin ophthalmic suspension 5%), an ocular antifungal, are Eyevance’s latest milestones in its growth strategy, the release said.

“The acquisition of Tobradex ST and Natacyn further demonstrates Eyevance’s commitment and mission to serve the doctors that treat patients’ anterior segment and ocular surface conditions,” Jerry St. Peter, Eyevance co-founder, CEO and director, said in the release. “Today’s market conditions and broad payer coverage position both products for strong, sustained growth.”

Financial details of the acquisitions were not released.